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Anoikis, a cell death mechanism triggered upon cell-matrix detachment, is regarded as a physiological suppressor
of metastasis that can be regulated by a diverse array of signals. The protein encoded by GDF2 is BMP9 and is a
member of the bone morphogenetic protein family and the transforming growth factor (TGF) β superfamily with
emerging yet controversial roles in carcinogenesis. In an attempt to identify the function of growth and
differentiation factor 2 (GDF2) in epithelial systems, we examined the signaling machinery that is involved and cell
fate decisions in response to GDF2 in ovarian and breast epithelia. We find that GDF2 can robustly activate the
SMAD1/5 signaling axis by increasing complex formation between the type I receptor serine threonine kinases
activin receptor-like kinase (ALK) 3 and ALK6 and the type II receptor serine threonine kinase BMPRII. This
activation is independent of cross talk with the SMAD2-transforming growth factor β pathway. By activating
SMAD1/5, epithelial cells regulate anchorage-independent growth by increasing anoikis sensitivity that is
dependent on GDF2’s ability to sustain the activation of SMAD1/5 via ALK3 and ALK6. Consistent with a role for
GDF2 in promoting anoikis susceptibility, the analysis of cell lines and patient data suggests epigenetic silencing
of GDF2 in cancer cell lines and increased promoter methylation in patients. These findings collectively indicate an
antimetastatic role for GDF2 in ovarian and breast cancer. The work also implicates loss of GDF2 via promoter
methylation-mediated downregulation in promotion of carcinogenesis with significant relevance for the use of
epigenetic drugs currently in clinical trials.
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Transforming growth factor (TGF)-β superfamily members play
distinct roles in tumorigenesis, acting to promote advanced-stage
cancers whilst inhibiting the early events in the processes that lead up
to it [1]. BMP9, also known as growth and differentiation factor 2
(GDF2), and BMP10 form a subgroup within the TGF-β
superfamily based on similarities in their primary amino acid
sequences and overlapping functions in the context of angiogenesis
[2–4]. Although the roles of GDF2 as an inducer and inhibitor of
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there is little insight into the functions of GDF2 in cancers of
epithelial origin. The relevance of GDF2 signaling in nonendothelial
cells stems from the finding that GDF2 is expressed in the liver,
mediates ectopic bone growth [9], is a differentiation factor for
cholinergic neurons of the central nervous system [10], and induces
proliferation of cultured cells [11–13]. Studies in hepatocytes have
shown that GDF2 is proliferative in transformed cells with no
changes in proliferative capacity of immortalized hepatocytes [13].
Additionally, GDF2 has also been shown to suppress breast cancer
in vivo [14].
GDF2 signaling in endothelial cells is initiated upon its binding to
the heteromeric type I/type II receptor. Two different type I receptor
serine threonine kinases have been implicated in GDF2 signaling:
activin receptor-like kinase (ALK) 1 in endothelial cells [5,15] and
ALK2 in other cell types [5,13,16]. Three type II receptors are part of
the GDF2 signaling complex: BMP type II receptor (BMPRII) and
activin type II receptors A and B (ActRIIA and ActRIIB) [5,16].
However, type I and type II receptor specificity maybe cell type
dependent, involving more than one type I [5] or type II receptors
[16]. Receptor activation upon ligand binding then activates the
receptor regulated SMADs (R-SMAD) SMAD1, SMAD5, and
SMAD8, allowing complex formation with the co-SMAD SMAD4,
nuclear translocation of the complex, and target gene regulation [17].
Ovarian and breast cancers are the two most lethal of women’s
cancers. In HER2-positive breast cancer cells, GDF2 treatment has
been shown to decrease HER2 protein and transcript levels and
reduce tumor volume in nude mice [18]. In contrast, GDF2 has been
shown to mediate pro-proliferative effects through the ALK2/
SMAD1/SMAD4 pathway in epithelial ovarian cancer cells [16].
Although there is very little known about the specific mechanisms of
GDF2 signaling in breast cancer, there is also a gap in the
understanding of GDF2 function in ovarian cancers. Contrary to
our notion of the origin of ovarian cancer, a systematic study of the
pathology of non-neoplastic tubular cells of the fimbriae in women
with familial BRCA1/2 mutations revealed the significance of the
tubular cells as the site of onset for serous ovarian carcinoma [19].
The transformation of primary human fallopian tube epithelial cells
(FTECs) and its subsequent injection in SCID mice have also
demonstrated the indistinguishable histology and transcriptional
profile between the xenograft and cells from patient-derived serous
ovarian cancer [20]. Thus, the protumorigenic or antitumorigenic
potential of GDF2 in experimental conditions of breast and ovarian
cancer that closely mimics physiological states of disease is still a
subject of critical relevance. In addition, the contribution of the
transformation status to GDF2-mediated mechanisms of cancer
evasion also remains unexplored.
In this study, we investigate the biological outcome of GDF2
signaling in normal and transformed breast and FTECs. We show
that functional GDF2 signaling as seen from SMAD1/5 phosphor-
ylation, nuclear translocation, and ID1 target gene expression occurs
via ALK3 and ALK6 type I receptors in cell lines with relatively high
ALK3 and ALK6 levels. We also show that in the presence of equal
amounts of ALK2, ALK3, and ALK6, GDF2 specifically potentiates
binding between ALK3 and ALK6 with the type II receptor BMPRII.
Interestingly, although we do not find a significant change in cell
proliferation upon GDF2 treatment, GDF2 significantly enhances
anoikis/anchorage independent growth via the ALK3/ALK6/SMAD1
axis. Reducing the activity of ALK3, ALK6, or SMAD1 abrogatesGDF2-dependent anoikis sensitivity, thereby demonstrating the
requirement of intact ALK3 and ALK6 signaling to SMAD1/5 to
confer anoikis sensitivity in ovarian and breast epithelial cells. We find
that reduced GDF2 protein levels in several cancer lines are consistent
with GDF2 promoter methylation observed in ovarian cancer
patients compared with normal counterparts. Bisulfite sequencing
confirmed that GDF2 promoter methylation and demethylation
correlated with reexpression of GDF2 in transformed cells,
implicating epigenetic silencing of the GDF2 pathway in cancer.
Materials and Methods
Cell Lines and Culture Conditions
Normal FTECs P210 and P211 and the transformed FTEC P76
were generated as described [20]. Ovarian teratoma and epithelial
carcinoma cell lines PA1, SKOV3, and OVCA429 were obtained
from Duke Gynecology/Oncology Bank, and the immortalized
ovarian surface epithelial cells IOSE80 and IOSE144 were obtained
from Canadian Ovarian Tissue Bank. Authentication of the cell lines
from the Duke Gynecology/Oncology Bank was carried out at the
UC Denver sequencing facility. All other cell lines used in this study
were obtained from ATCC.
FTECs: P210, P211, P76, murine mammary carcinoma cell line:
67NR, 4T1, and HEK293 cells were grown in complete DMEM
supplemented with L-glutamine, 10% fetal bovine serum (FBS) and
100 U of penicillin-streptomycin. Epithelial carcinoma cell lines:
PA1, SKOV3, and OVCA429 were cultured in RPMI containing
L-glutamine, 10% FBS, and 100 U of penicillin-streptomycin. The
normal human mammary epithelial cell line MCF10A was cultured
in F12/DMEM (1:1) supplemented with 5% horse serum, 10 μg/ml
of insulin, 0.5 μg/ml of hydrocortisone, 20 ng/ml of EGF, and
100 ng/ml of cholera toxin. Humanmammary epithelial cell (HMEC)
lines were grown in complete HMEC media containing bovine
pituitary extract (Clonetech#CC-2551). Immortalized ovarian surface
epithelial cells IOSE80 and IOSE144 were maintained in
M199:MCDB105 medium (Invitrogen #11150, Sigma #M6395)
with 5% FBS. All cells lines were maintained at 37°C in a humidified
incubator at 5% CO2.
Antibodies, Reagents, and Plasmids
Antibodies phosphoSMAD1/5 (#9516S), BMPRII (#6979),
cleaved caspase 3 (#9661), caspase 3 (#9662), BIM (#2819),
HA-Tag rabbit (#C29F4), and SMAD1 (#6944S) were from Cell
Signaling Technology. Total SMAD1/5 (#sc-6201), ID1 (#365654),
and GDF2 (#130703) were from Santa Cruz Biotech. Actin
(#A2228) was from Sigma, and anti-HA antibody (#32-6700) was
from Invitrogen. Inhibitors SB431542 hydrate (#S4317), dorsomor-
phin (#p5499), 5-azacytidine (#A2385), TAK inhibitor 5 Z-7-
oxozeaenol (#O9890), and trichostatin A (#T8552) were from Sigma.
ALK1/2 inhibitor ML347 (#4945) was from Tocris Bioscience.
Pan-caspase inhibitor z-vad-fmk (#fmk001), Alk1-ECD
(#370-AL-100), TGFβ, BMP2, GDF2, and BMP10 were from
R&D Systems. Constructs expressing ALK2-Flag, ALK3-HA,
ALK6-HA, ALK3 (KR)-HA and ALK6 (KR)-HA, BRE-Luc,
PE2.1, and P3TP were a kind gift from Miyazono K. [21]. shRNA
constructs to ALK2, ALK3, ALK6, and BMPRII were obtained from
Sigma (Supplementary Table 1A). For SMAD1 knockdown, PA1
cells were infected with 100 MOI of SMAD1 shRNA adenovirus
construct, generously provided by Maria Trojanowska. Q-PCR
primer sequences and primers designed to the CpG1 site of the
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Lipofectamine 2000 (#11668019) was from Life Technologies, and
Duolink to measure proximity ligation was from OLink Bioscience.
Caspase-Glo 3/7 Assay System (Promega #G8090) and MTT reagent
were obtained from Amresco.
Luciferase Assay
Cells were transfected with the BRE-Luc reporter plasmid.
Treatment with BMP4 (10 nM) or GDF2 (10 ng/ml) was carried
out for 24 hours after 6 hours of serum starvation. Cells were collected
and lysed in 1× passive lysis buffer (Promega) according to
manufacturer’s instructions. To measure luciferase activity, 20 μl of
lysate was added to 25 μl of Luciferase Assay Reagent (Promega), and
luminescence was quantitated using a luminometer (Biotek). Where
indicated, dorsomorphin treatment concentrations were at 3 μM.
Cell Lysis and Immunoprecipitation
Cells were lysed in SDS lysis buffer for immunoblot analysis. For
co-immunoprecipitation, HEK293 cells were lysed in nondenaturing
E1A lysis buffer (50 mM HEPES pH 7.5, 150 mM of NaCl, 0.1%
Nonidet P-40, 0.2 mM PMSF, 1 mg/ml of aprotin, and 1 mg/ml of
leupeptin).
Anoikis Assay
For anoikis assay, 400,000 cells were plated on poly-HEMA–
coated 12-well plates. Cells were harvested at specified times
following treatment with GDF2, washed with 1× PBS, and lysed
for immunoblot analysis. For the MTT assay, cells grown on
poly-HEMA–coated plates for the indicated times were collected and
reseeded on tissue culture plates and allowed to reattach overnight,
and MTT solution at a final concentration of 1 mM was added. The
plates were incubated in a 37°C incubator for 2 to 3 hours, DMSO
was added to dissolve the formazan crystals, the supernatant was
pipetted in triplicates in a 96-well plate, and absorbance measured
using a Synergy HT plate reader at 570 nm. Caspase-Glo Assay to
quantify active caspase 3/7 was carried out according to manufac-
turer’s instructions (Promega #G8090).
GDF2 ELISA
The GDF2 ELISA was performed according to manufacturer’s
instructions (R&D Systems, #Dy3209). Briefly, 90,000 cells were
plated in triplicate in a 96-well plate. After the cells adhered to the
plate, medium was replaced to serum-free medium, and the assay
procedure was initiated after overnight incubation in serum-free
medium. GDF2 standards ranged from 15 to 1000 pg/ml, and
absorbance values were calculated from the difference between OD
450 nm and OD 570 nm to account for plate correction.
Growth of MCF10A Acini in Matrigel
The protocol for the growth of MCF10A acini was as previously
described [22]. Briefly, cells were seeded on Matrigel-coated chamber
slides in media containing 2% Matrigel in the presence or absence of
20 ng/ml of GDF2 treatment or in the presence or absence of 20 μM
z-vad-fmk. Acini growth was monitored and documented at day 10.
Immunofluorescence and Microscopy
Cells were fixed in 4% paraformaldehyde, permeabilized in 0.3%
TX-100, and blocked with 1% BSA PBS. Primary antibody (1:200)
incubation for an hour was followed by 30-minute incubation with
Alexa Fluor 488 (H+L) (#A11008 Life Technologies). After washing,cells were stained with 4′6-diamidino-2-phenylindole (Roche).
In situ proximity ligation assay was carried out according to
manufacturer’s instructions. Imaging and z-stacking were performed
using a Zeiss LSM700 confocal microscope.
Quantitative Polymerase Chain Reaction (qRT-PCR)
For qRT-PCR, total RNA was isolated from approximately
200,000 cells using Trizol reagent (Invitrogen, Carlsbad, CA).
RNA was retrotranscribed using the 5× reaction mix (#R1362,
Thermo Scientific) and the Maxima Enzyme Mix (#K1642, Thermo
Scientific). qRT-PCR primer sequences are listed in Supplementary
Table 1B.
GDF2 Promoter Methylation Analysis
GDF2 promoter methylation from genomic DNA obtained from
patient samples was validated as described [23]. Bisulfite sequencing
to quantify methylation at the CpG site within the GDF2 promoter
was carried out as previously described [24]. Briefly, bisulfite
conversion was performed with 800 ng of DNA. PCR and
pyrosequencing assay were designed and performed using Qiagen
PyroMark assay design software and kit (Supplementary Table 1C).
The assay was validated with different proportions of methylated and
unmethylated DNA, and the correlation curve (R2 = 0.98) was
generated and compared with the input (data not shown).
Results
BMP9/GDF2 and not BMP10 activates SMAD1/5 in both
normal and oncogenic Ovarian and Breast epithelial Cells
Given that GDF2 and BMP10 have been identified as ALK1
ligands in endothelial cells [6], their role in normal and oncogenic
epithelial cells that express low levels of the endothelial specific
ALK1 receptor remains unclear [25] (Supplementary Figure S1A).
To ask whether GDF2 treatment would engage downstream
signaling events in nontumorigenic and transformed ovarian and
breast epithelial cancer cell lines, a time-course analysis of SMAD1/5
phosphorylation was carried out in a panel of breast and ovarian cell
lines. Ovarian surface epithelial cells were previously considered as
suitable in vitro models of serous ovarian carcinoma, whereas recent
work has shown that the molecular determinants that recapitulate
the disease arise from tubular cells of the fimbriae [20]. To
investigate the response of an experimental model that closely
mimics the site of origin of serous carcinoma, we treated
immortalized FTEC P211 [20] and the normal breast epithelial
cell line MCF10A with GDF2 for the indicated times (Figure 1A).
An identical pulse of GDF2 was also carried out in the oncogenic
P76, an FTEC line transformed with an oncogenic cocktail [20], in
the ovarian teratoma cancer cell line PA1 isolated from ascites [26]
and in the breast cancer lines 4T1 and 67NR. Robust SMAD1/5
phosphorylation was seen as early as 15 minutes after GDF2
treatment (Figure 1, A and B). A dose course with GDF2 also
confirmed the sensitivity of the epithelial cell lines to GDF2
signaling (Supplementary Figure S1, B and C). Because prior studies
have indicated that BMP superfamily members (BMP2/4) can
activate the SMAD2/3 pathways as well [27], we examined
SMAD2/3 signaling in these cell lines. Whereas TGF-β activated
SMAD2/3 in 30 minutes, GDF2 did not phosphorylate SMAD2/3
and did not activate the CAGA promoter specific for TGFβ-induced
SMAD2/3 activation (Supplementary Figure S1, D and E). Thus,
GDF2 led exclusively to SMAD1/5 phosphorylation.
Figure 1. GDF2 activates SMAD1/5 in breast and ovarian epithelial cells. (A) Western blotting of lysates from untransformed breast
(MCF10A) and FTEC line FTEC 211 treated with GDF2 (10 ng/ml) for the indicated times and immunoblotted for pSMAD1/5 and SMAD1/5.
(B) Western blotting of lysates from transformed breast cancer lines 4T1 and 67NR including the transformed oncogenic FTEC P76 and
ovarian cancer line PA1 treated as in (A) and immunoblotted for pSMAD1/5 and total SMAD1/5. (C) SMAD1/5 translocates to the nucleus.
Immunofluorescence images of 4T1 cells treated with GDF2 for 30 minutes followed by immunostaining for SMAD1/5. Overlay images
are shown with the nuclear stain 4′6-diamidino-2-phenylindole. (D) GDF2 specifically induces BRE-luciferase promoter activity. Luciferase
activity (Methods) of either BMP4 (10 nM)– or GDF2 (10 ng/ml)–treated MCF10A, p76, and PA1 cells as indicated normalized to untreated
cells is presented. (E) ID1 target protein expression. Western blotting for ID1 in 4T1 and 67NR cells treated with GDF2 at indicated time
points. Loading control was actin. (F) pSMAD1/5 phosphorylation in response to BMP10 is less robust compared with GDF2. Western
blotting of MCF10A and PA1 lysates treated with 10 ng/ml of GDF2 or BMP10 for the indicated times.
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observed distinct nuclear translocation of SMAD1/5 (Figure 1C) and
the activation of the BMP response element (BRE-Luc) [28] in
response to GDF2 treatment (Figure 1D). In accordance with
promoter activity, protein levels of ID1, a direct target of BMPs [29],
also increased upon GDF2 treatment (Figure 1E).
Because BMP10 is most closely related to GDF2 among the GDF/
BMP family, we also investigated the activation of SMAD1/5
phosphorylation in response to BMP10. Little to no activation of
SMAD1/5 phosphorylation was seen upon BMP10 treatment in two
independent cell lines (Figure 1F). These data suggest that GDF2 is a
robust activator of SMAD1/5 in epithelial cells, causes nuclear
translocation of SMAD1/5, and induces SMAD1 target gene and
protein expression in both breast and ovarian epithelial cells.
GDF2-induced SMAD1 signaling is mediated via BMPRII-
ALK3 and BMPRII-ALK6
TGF-β superfamily members activate signaling by binding and
activating specific type I (ALK2, 3,4,5,6,7) and type II serine
threonine kinase receptors with the BMP superfamily member
initiating signaling through interactions with the type I receptor [30].
Prior studies have indicated cross talk between BMP and the TGF-β
receptor serine threonine kinases as well [27]. Thus, to investigate
which type I receptor was required for GDF2-induced SMAD1
phosphorylation, we first examined basal expression of type I and type
II receptors in the cell lines used. Interestingly, MCF10A cells
expressed relatively higher levels of ALK2, whereas all other cell lines
examined expressed relatively higher levels of ALK3 (Supplementary
Figure S2A), a trend that is in accordance with the NCI60 panel of
breast and ovarian cancer lines [31,32]. We tested GDF2-induced
SMAD1/5 phosphorylation in the presence of dorsomorphin, an
inhibitor of ALK2, ALK3, and ALK6 [33], or SB431542, an
inhibitor of ALK4, ALK5, and ALK7 [34]. Although treatment with
SB431542 clearly inhibited TGFβ-induced SMAD2/3 phosphoryla-
tion (Supplementary Figure S2B), SMAD1/5 phosphorylation in
response to GDF2 was abrogated specifically in the presence of
dorsomorphin (Figure 2A). Because dorsomorphin blocks ALK2, 3,
and 6, we sought to examine the involvement of ALK2 in mediating
the SMAD1/5 phosphorylation in response to GDF2. We used
ML347, an ALK2 inhibitor with a N300-fold selectivity for ALK2
compared with ALK3 [35]. GDF2-induced SMAD1/5 phosphory-
lation was dampened by ML347 to a greater extent in MCF10A cells
that express high levels of ALK2 (Figure 2B, Supplementary Figure
S2C) compared with SMAD1/5 activation in PA1 cells that express
high levels of ALK3 (Figure 2B, Supplementary Figure S2A). These
data confirm prior studies on the roles of ALK2 in mediating GDF2
signaling [16] but, importantly, point to ALK3/ALK6 as being used
with equal efficiency to ALK2 by GDF2 to activate SMAD1/5. To
confirm the effects of the inhibitors to the type I receptors and to
investigate the type II receptor that cooperates with the type I receptor
in activating the SMAD1/5 pathway, we independently knocked
down ALK2, ALK3, ALK6, and BMPRII using shRNA (Figure 2, C
and D). GDF2-activated SMAD1/5 phosphorylation was abrogated
upon reducing expression of ALK3, ALK6, or BMPRII (Figure 2C),
with a much more modest effect upon loss of ALK2, consistent with
our inhibitor experiments (Figure 2, A and B). As a third approach,
to strengthen our findings on the involvement of ALK3 and ALK6 in
mediating SMAD1/5 phosphorylation, we carried out a time-course
analysis on SMAD1/5 phosphorylation in the presence of ALK3 K-Rand ALK6 K-R, the respective kinase-inactive and dominant negative
forms of ALK3 and ALK6, [21] in PA1 and MCF10A cells
(Figure 2E). Both ALK3 K-R and ALK6 K-R were able to effectively
reduce SMAD1 phosphorylation following GDF2 treatment in both
cell lines (Figure 2E).
Consistently, luciferase activity upon GDF2 treatment also showed
reduced transcriptional SMAD1/5 response in cells treated with
dorsomorphin, confirming the involvement of ALK3 and ALK6 in
GDF2-induced SMAD1/5 activation (Figure 2F). The inhibitor
treatments, shRNA, andmutant approach together indicate a dominant
role for ALK3/ALK6 in GDF2-induced SMAD1/5 activation.
GDF2 enhances complex formation between BMPRII-ALK3
and BMPRII-ALK6
Given the role of ALK3, ALK6, and BMPRII in GDF2-induced
SMAD activation, we asked whether GDF2 stimulated specific
BMPRII interactions with ALK3 and ALK6. Although ALK3 and
ALK6 co-immunoprecipitated with endogenous BMPRII at steady
state consistent with prior studies demonstrating complex formation
between the two receptors at the basal level [36], GDF2 treatment
enhanced the interaction between each of the type I receptors (ALK3
and ALK6) and BMPRII (Figure 3, A and B). To complement the
co-immunoprecipitation studies and visualize this interaction, we
used a proximity dependent ligation assay [37] to examine and
quantify proximity of the two type I receptors and BMPRII in
unstimulated and GDF2 stimulated cells. Consistent with the
co-immunoprecipitation, ALK3 and ALK6 interaction with endoge-
nous BMPRII was increased in response to GDF2 (Figure 3, C and D,
two-fold **P b .01). However, BMPRII and ALK2 interactions were
unaffected (Figure 3, C and D). Thus, GDF2 specifically increased the
respective interactions between ALK3 and ALK6 with BMPRII.
GDF2 increases anoikis sensitivity of epithelial cells via ALK3/
ALK6/SMAD1
One common cellular event in the initiation and metastasis of
breast and ovarian cancer, respectively, is the ability of epithelial cells
to become anoikis resistant and overcome anchorage-dependent
growth [38,39]. Therefore, we sought to examine if GDF2 provided
any survival advantage under anoikis conditions. Using the GDF2
dose that ubiquitously induced SMAD1/5 signaling (10 ng/ml for
PA1 and 10-20 ng/ml for 4T1 (Supplementary Figure S1), we find
that, in ovarian, breast, and FTECs (PA1 and 4T1 and P76), GDF2
increased anoikis sensitivity (2- to 10-fold) as measured by an increase
in cleaved caspase 3 (CC3) levels as early as 6 hours after
anchorage-independent growth (Figure 4A). In addition, the
proapoptotic protein Bim also increased in the presence of GDF2
under anoikis conditions (Supplementary Figure S3A). A secondary
quantitative approach examining caspase 3/7 activity also indicated a
significant increase [40] following GDF2 treatment (Supplementary
Figure S3B) consistent with the increased CC3 (Figure 4A). In
addition, cell viability after anoikis in the presence and absence of
GDF2 as measured by an MTT assay in two different cell lines
(transformed FTEC P76 cells and transformed breast cell line 4T1)
also revealed significant decreases in cell viability in response to GDF2
(Figure 4B). Because our data collectively point to an increase in
anoikis sensitivity following GDF2 treatment, we wanted to
investigate the effects on long-term survival and proliferation.
Mammary epithelial cells MCF10A form spheroids upon growth in
Matrigel [22], and normal morphogenesis triggers anoikis between
day 8 and day 10 [22]. To study long-term anchorage-independent
Figure 2. ALK3 and ALK6 are required for GDF2-induced SMAD1/5 phosphorylation. (A-B) Western blotting for pSMAD1/5 activation in
PA1 andMCF10A cells in the presence and absence of dorsomorphin 1 μM (+) or 3 μM (++), SB431542 3 μM (+) or 5 μM (++), or ML347
500 nM (+) or 1 mM (++) as indicated with and without GDF2 (10 ng/ml) as indicated (quantification of pSMAD1/5 levels presented in
Supplementary Figure S2C). (C) Immunoblotting of pSMAD1/5 in PA1 cells in the presence of shRNAs to ALK2, ALK3, ALK6, and BMPRII
without and with GDF2 treatment (10 ng/ml) for 30 minutes. (D) QRT-PCR analyses of (C) to confirm reduced expression of ALK2, ALK3,
ALK6, and BMPRII expression as indicated. (E) Kinase inactive ALK3 and ALK6 inhibit SMAD1/5 phosphorylation. Western blotting as
indicated in MCF10A and PA1 cells in the presence of either mock transfected or HA-tagged kinase inactive ALK3 (ALK3 K-R) or ALK6
(ALK6 K-R) and treated with GDF2 for the time points indicated. Actin was the loading control. (F) Dorsomorphin inhibits SMAD1/5
transcriptional activation. BRE-luciferase reporter activity in indicated cells in the absence (GDF2 alone) or presence of 1 μM
dorsomorphin (GDF2+DM). Fold induction of luciferase activity compared with DMSO-treated control cells is presented.
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Figure 3. ALK3 and ALK6 interact with BMPRII upon treatment with GDF2. (A-B) HEK293 cells expressing either (A) ALK6-HA or (B)
ALK3-HA with or without stimulation for 30 minutes with GDF2 were lysed, immunoprecipitated with anti-HA, and immunoblotted for
endogenous BMPRII and HA as indicated with assessment of 10% of the protein lysate for input. Actin was the loading control. (C-D)
GDF2 specifically increases BMPRII-ALK3 and BMPRII-ALK6 interaction. Fluorescent images of proximity ligation in PA1 cells between
ALK3-HA, ALK6-HA, or ALK2-Flag, with endogenous BMPRII, with or without GDF2 as described in methods. Dots are representative of
protein proximity and interaction. (D) Quantification of the interaction compared with control cells is presented. In PA1 cells, protein
interaction increased two-fold (**P b .01) in the ALK3-HA– and ALK6-HA–expressing cells; N = 50 per condition.
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offer a survival advantage in the presence of GDF2, we measured acini
size in the presence and absence of GDF2 over a period of 10 days and
in the presence or absence of pan-caspase inhibition. A significant
decrease in acini size in GDF2 treated cells was observed (***P b .001;
Figure 4C) that was partially rescued when apoptosis inhibition was
combined with GDF2 treatment (***P b .001). These data indicate
that acini in the presence of GDF2 induce anoikis significantly more
rapidly than control cells consistent with early and increased
activation of cleaved caspase 3 in response to GDF2 (Figure 4A).
Interestingly, we observed little to no change in the proliferative
capacity of cells treated with GDF2 for up to 5 days and grown under
adherent conditions (Supplementary Figure S3, C and D).
To begin to determine the mechanism by which GDF2 regulated
anoikis sensitivity, we asked whether GDF2 induces SMAD1
phosphorylation under anoikis conditions as well. Surprisingly, in
both the ovarian and breast epithelial cell lines, GDF2 induced and
sustained SMAD1/5 phosphorylation under anoikis (Figure 4D)
compared with control cells, pointing to a possible link between
GDF2-induced sustained SMAD1 activation and anoikis sensitivity.
To investigate the biological significance of ALK3/ALK6/
SMAD1 activation in anoikis sensitivity, we carried out the anoikis
assay in PA1 cells in the presence of dorsomorphin, which inhibitsGDF2-induced SMAD 1/5 phosphorylation (Figure 2A). Dorso-
morphin treatment suppressed GDF2-induced anoikis sensitivity, as
evident from the decrease in levels of CC3 (Figure 5A, Supplementary
Figure S3E), implicating SMAD1 in mediating GDF2-induced
anoikis. Because our data have established the involvement of the type
I receptors ALK3 and ALK6 in SMAD1/5 phosphorylation
(Figure 2), we wanted to evaluate the contribution of ALK3 and
ALK6 in GDF2-induced anoikis. Whereas anoikis was evident 24
hours after anchorage-independent growth, dominant negative ALK3
(ALK3 K-R) was able to suppress anoikis more rapidly at the 24-hour
time point compared with dominant negative ALK6 (ALK6 K-R).
However, compared with mock transfected controls, both ALK3 K-R
and ALK6 K-R were able to suppress GDF2-induced anoikis at the
48-hour time point (Figure 5B, Supplementary Figure S3F). These
data collectively indicate that GDF2-induced SMAD1/5 phosphor-
ylation is sustained under anoikis conditions, is required for anoikis
sensitivity, and is mediated via ALK3 and ALK6. To confirm the roles
of ALK3/ALK6 and SMAD1 in enhancing anoikis sensitivity, we
used shRNA to reduce ALK3, ALK6, and SMAD1 and measured
anoikis upon GDF2 treatment. We find that GDF2 induced CC3
and cell viability was reduced upon lowering ALK3 and ALK6 levels
by shRNA (Figure 5, C and D). Similarly, GDF2-mediated anoikis
was also reduced upon lowering expression of SMAD1 using shRNA
Figure 4. GDF2 stimulates anoikis. (A) Indicated cell lines were plated for anoikis as described in Methods on poly-HEMA–coated plates
and treated with either 10 ng/ml (+) or 20 ng/ml (++) of GDF2. Western blotting for CC3 and actin is presented. Normalized densitometry
analysis of CC3 intensities is presented below. (B) Absorbance values using the MTT assay (Methods) after anoikis for 24 hours with
different concentrations of GDF2 are presented. Data are representative of two independent experiments (*P b .05 and ****P b .0001 in
p76 and 4T1 cells, respectively). Error bars indicate SEM. (C) Acini size of MCF10A cells grown on growth factor reduced Matrigel with or
without 20 ng/ml of GDF2 in the presence or absence of pan-caspase inhibitor Z-VAD-FMK for 10 days is presented. Mean acini width is
quantified (***P b .01). N = 30; error bars indicate SEM. (D) Western blotting of same cell lysates prepared as described for (A) was
probed for pSMAD1/5 and total SMAD1/5. Actin was the loading control.
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studies point to a role for SMAD1 in GDF2-mediated anoikis,
GDF2 has been shown to use non-SMAD mechanisms such as
TAK1 (TGFβ activated kinase) to activate endothelial specific
genes [41]. Thus, to determine if TAK1 was required for
GDF2-induced anoikis, we used the TAK1 inhibitor 5Z-7-oxozeaenol (Methods) to test GDF2-mediated anoikis. We find
that GDF2-mediated anoikis was not suppressed by TAK1
inhibition (Supplementary Figure S3H) but rather was slightly
enhanced, suggesting a TAK1-independent role for GDF2 on
anoikis. These data collectively point to a central role for the ALK3/
ALK6/SMAD1 axis in mediating anoikis.
Figure 5. Anoikis susceptibility is mediated via ALK3/ALK6. (A) Western blotting of 4T1 cells grown under anoikis conditions either with or
without 1 μM dorsomorphin and GDF2 as indicated. Lysates were immunoblotted against CC3. Actin was the loading control
(quantification of CC3 levels presented in Supplementary Figure S3E). (B) Kinasemutants ALK3 K-R and ALK6 K-R reduce anoikis. Western
blotting of PA1 cells expressing control, ALK3 K-R, or ALK6 K-R was plated for anoikis (Methods) in the absence or presence of GDF2 for
indicated times (quantification of CC3 levels presented in Supplementary Figure S3F). (C) MTT absorbance values of PA1 cells expressing
shScr, shALK3 or shALK6 after 24 hours of anoikis in the absence and presence of 10 ng/ml of GDF2 are presented. Error bars indicate
SEM. (D) Western blotting of same cells as in (C) harvested after 24 hours of anoikis and immunoblotted for CC3. Actin was the loading
control. (E) Western blotting as indicated of PA1 cells expressing shSMAD1 or shScr at the indicated times under anoikis conditions
(quantification of CC3 presented in Supplementary Figure S3G). SMAD1 transcript levels upon shRNA to SMAD1 relative to controls are
presented in the adjacent graph. Actin was the loading control.
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Our data point to an antitumorigenic function for GDF2 in in vitro
models of ovarian and breast cancer. We thus wanted to examine if
detectable differences exist between protein levels of GDF2 in
ovarian and breast cancer cell lines and their transformed
counterparts. We used immortalized ovarian surface epithelial
cells [42] FTECs [20], MCF10A, and HMEC to represent
untransformed cells and compared the level of GDF2 protein
levels with six cancer cell lines. Whereas GDF2 protein was
observed in all the six untransformed cells, five of the six cancer cell
lines tested had no GDF2 protein detectable (Figure 6A). Secreted
GDF2 protein levels by ELISA also correlated with the transfor-
mation status of the cells (Figure 6B).
Based on the reduced protein levels and putative roles for GDF2 in
increasing anoikis, we hypothesized that GDF2 expression was
epigenetically silenced in cell lines and patient samples of ovariancancer. To determine if GDF2 expression was transcriptionally
repressed and if so via recruitment of DNA methyl transferases, we
examined GDF2 levels in PA1 cells in the presence or absence of
azacytidine (AZA) a strong inducer of protein demethylation [43]
(Figure 6C). AZA treatment significantly increased GDF2 mRNA
levels in a dose- and time-dependent manner, suggesting an
epigenetic mechanism in the inactivation of GDF2 gene expression
possibly via methylation (Figure 6C). To determine whether GDF2
derepression by AZA treatment would enhance SMAD1/5 phos-
phorylation in an ALK3- and ALK6-dependent manner, we measured
SMAD1/5 phosphorylation under anoikis conditions in the presence
of AZA. In accordance with our previous observation on the role of
GDF2 and SMAD1 in anoikis, we found that AZA treatment
increased SMAD1/5 phosphorylation, CC3, and anoikis sensitivity
(Figure 6D). Consistent with GDF2-induced anoikis via ALK3/
ALK6 (Figure 5) and AZA-induced increase in GDF2 levels and
anoikis (Figure 6, B and C), dorsomorphin treatment inhibited
Figure 6.GDF2 expression in breast and ovarian cells. (A) Indicated cell lines were lysed and immunoblotted for GDF2 (*lower band). Actin
was the loading control. (B) Secreted GDF2 levels as determined using ELISAs in indicated breast and ovarian cell lines. (C) QRT-PCR
levels of GDF2 transcript in the presence of increasing AZA for the indicated time points. Error bars indicate SEM. (D) Western blotting for
CC3 and pSMAD1/5 in PA1 cells either untreated or treated with AZA under anoikis conditions for the indicated times. Dorsomorphin (5μM)
was added in combination during anoikis where indicated (Dm). Actin was the loading control. (E) Promoter methylation of GDF2. GDF2
promotermethylation statusof ovarian cancer patients (N=47; black line) plotted against normal fallopian tubeepithelium (gray line) from the
same experiment. Values were plotted using the GraphPad Prism software. Beta values are presented (*P b .05). (F) Percent methylation
determined by pyrosequencing (Methods and Supplementary Table) of the CpG1 site contained within the GDF2 promoter in either
untransformed P211 or transformed PA1 cells in the presence or absence of 1 μM AZA is presented.
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quenching using Alk1-ECD, which has been used as a ligand trap
for GDF2 [44,45], dampened the effects of AZA-induced anoikis
(Supplementary Figure S3I), consistent with increased GDF2 levels
in response to AZA (Figure 6C). These data indicate that
methylation-mediated reduction in GDF2 expression may lead to
anoikis resistance in cancer.
To extend our findings on GDF2 repression in cancer cell lines, we
examined the methylation status of the GDF2 promoter in ovarian
cancer patients. We plotted HumanMethylation450 BeadChip beta
values using a methodology previously described [23] for a panel of
47 high-grade advanced-stage serous epithelial ovarian cancers and 4
normal fallopian tube fimbriae epithelium specimens across the
GDF2 locus (Figure 6E). GDF2 was more highly methylated (*up to
15% increase *P b .05) in the GDF2 promoter region of tumors from
ovarian cancer patients (n = 47) as compared with the fallopian tube
fimbriae epithelium of normal individuals (Figure 6E). These data
point to increased DNA methylation in serous ovarian cancer
compared with normal precursor cells consistent with its putative role
as a tumor-suppressing factor in these cancers. To experimentally
validate our finding on the methylation status of the GDF2 promoter,
we carried out pyrosequencing analyses of the same CpG1 site in
nononcogenic P211 where GDF2 expression was detected
(Figure 6A) and PA1 cells that had little to no detectable GDF2
(Figure 6A) and investigated whether AZA treatment would reduce
methylation at the CpG1 site within the GDF2 promoter
(Figure 6E*). We find that methylation levels decreased in the
ovarian cancer cell line PA1 following AZA treatment (Figure 6F)
consistent with increased expression of GDF2 upon AZA treatment
(Figure 6C). Control, untransformed FTEC P211 cells that already
express GDF2 (Figure 6A) showed no methylation regulation in the
presence of AZA. These data indicate that GDF2 expression is
repressed by promoter methylation in patient samples and cancer cell
lines (Figure 6) and that reexpression can trigger SMAD1/5 signaling
and anoikis sensitivity (Figure 6D, Supplementary Figure S3I).
Discussion
Our study shows for the first time a role for GDF2-induced SMAD1/
5 activation via ALK3/ALK6 during anoikis in breast and ovarian
epithelial models (Figure 1, A and B). Although BMP10 bears
sequence similarity with GDF2 and is a functional equivalent in
binding the type I receptor ALK1 [6,15], BMP10 activation of the
SMAD1/5 pathway is significantly less compared with the extent and
kinetics of SMAD1/5 activation by GDF2 (Figure 1, F, right panel).
This distinction is rather significant and may explain the similar yet
disparate roles of GDF2/BMP9 and BMP10 in cardiac development
as well [4]. Although ALK3- and ALK6-dependent BMP10 activity
has been observed in osteoblast precursor cells [46], it is likely that
lineage-specific utilization of specific type I receptors or ligand
heterodimerization may account for this variability [47]. Our data are
also supportive of an ALK1-independent tumor suppressive role for
GDF2 consistent with in vivo studies in breast cancer [14].
The role of GDF2 in tumorigenesis is somewhat unclear because it
has been shown to promote ovarian cancer cell growth [16], suppress
breast tumorigenesis [48], and increase hepatocellular carcinoma cell
growth [13]. The mechanisms behind these pleiotropic effects remain
largely unknown. Elucidating the specific biological outcomes and the
receptor signaling mechanisms mediated by GDF2 may shed light on
the contexts under which GDF2 is a tumor promoter or a suppressor.Previously, ALK2 has been shown to interact with GDF2 [16];
however, our studies indicate a strong preference for ALK3 to induce
SMAD1 activation when expressed at equal or higher levels than
ALK2, pointing to possible tissue/cancer-specific or type I receptor
(ALK)–specific roles for GDF2 that may dictate tumor growth and
response. The molecular determinants that drive subtype-specific
receptor interaction in response to GDF2 cannot be ascertained from
mRNA levels of the type I and type II receptors alone (Supplementary
Figure S2A). Posttranslational modification and subsequent protein
stabilization as in the case of ALK3 might contribute to preferential
interaction and outcome [49]. Although this study examines the role
of ALK3 and ALK6 in GDF2-mediated signaling and anoikis, the
contribution of individual receptor subtype has not been elucidated.
Context-dependent precedence of ALK3 or ALK6 might mediate
specific signaling and function.
Ovarian cancer aggressiveness has been associated with anoikis
resistance, a mechanism adopted by neoplastic cells to evade cell death
[38]. Similarly, in breast cancer, ductal carcinoma in situ exhibits
filling of the epithelial lumen indicating anoikis resistance as an early
event in initiation [50]. Accordingly, our data also show anoikis
sensitivity in response to GDF2 treatment and anoikis evasion upon
ALK3, ALK6, and SMAD1/5 inhibition (Figures 4 and 5). Further
studies to examine the precise mechanism used to induce anoikis
upon SMAD1/5 activation are warranted.
In our studies, we combined normal and transformed counterparts
to assess if GDF2 played differential effects depending on the
transformation status. We however saw no significant distinction in
signaling responsiveness in our breast and ovarian cancer models
based on transformation status. In contrast, there was a correlation
between the reduced expression of GDF2 and the transformation
status of breast and ovarian cell lines. Neoplastic cells have been
shown to contain regions of hypermethylation in tumor suppressor
genes. Consistently, GDF2 promoter was methylated in ovarian
cancer patients at the CpG1 site, which was experimentally confirmed
from our pyrosequencing analyses in our cell line panel (Figure 6F).
Gene expression can be controlled by multiple mechanisms over and
above methylation including histone modifications. Although our
data clearly demonstrate a role for methylation in the control of
GDF2 expression, it is unlikely the whole story, and future in-depth
studies on the control of GDF2 expression in patient populations
are warranted.
Our data provide new evidence on the role of GDF2 in cancers of
the breast and ovary/fallopian tube. It is interesting to note that
despite the low levels of GDF2 in the transformed cells (Figure 6, A
and B), the cells are competent to initiate downstream effectors upon
GDF2 treatments like their normal counterparts. Thus, GDF2
treatment or its reactivation could activate signaling sensitivity to
mediate anoikis sensitivity in cancer cells (Figure 6D). Prior studies
examining ovarian cancer tissues have revealed GDF2 staining in
25% of epithelial ovarian cancer with varying expression levels within
the epithelial ovarian cancer subtype. Nonepithelial ovarian tumors
do not express GDF2 [16]. Analyses of mRNA levels in breast cancer
and the adjacent tissues have also revealed increased GDF2 expression
in the adjacent nontumor tissues. Such distinctions in GDF2
expression between cancer subtype and proximity may correlate to
tumor stage or metastasis [14].
One of the most recent and consistent finds from high-throughput
screens in primary human tumor samples has been the high
frequencies with which genes encoding epigenetic regulators are
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promise as targets in the treatment of cancer [52,53], tumorigenicity
and metastasis were markedly suppressed when treated with
Trichostatin (TSA) and Azacytidine (AZA) in xenograft mouse
models of ovarian cancer [54]. From our findings, it is plausible that
GDF2 reexpression may play a partial role in sensitizing tumor cells to
epigenetic modifier-based therapies and could be complementary to
the common targets of cell proliferation and apoptosis.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2015.11.003.
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